Astraveus is a technology company.
Astraveus has raised $18.0M across 1 funding round.
Astraveus has raised $18.0M in total across 1 funding round.
Astraveus is a Paris-based biotech company developing the Lakhesys™ Benchtop Cell Factory, a proprietary microfluidic platform for fully automated, end-to-end production of cell therapies like CAR-T cells.[1][2][3][5] It serves biotech firms, research centers, and therapy developers by solving high manufacturing costs, scalability issues, and complexity in traditional cell and gene therapy (CGT) production, enabling decentralized, efficient processing in a compact benchtop system.[1][3][4] In January 2025, Astraveus achieved a milestone with the world's first end-to-end CAR-T cell production using microfluidics, and by May 2025, partnered with NecstGen for real-world evaluation; backed by €16.5M from investors like AdBio Partners, Bpifrance, Merck (M Ventures), and J&J (JJDC), plus €10.4M from France 2030, the company is advancing toward commercialization with active hiring.[1][2][3]
Astraveus was founded on July 7, 2016, at Saint-Louis Hospital in Paris by Jérémie Laurent, PhD, stemming from his thesis work on "biological computers" inspired by handling cells like data to spark a biotech industrial revolution, with cell therapy as the entry market.[2][4] Early years focused on self-funded research alongside grants from BPI France and the European Commission; after six years, a 12-person team delivered patented tech and a prototype proving the benchtop concept's viability.[2] This attracted major funding in a €16.5M Series Seed round from AdBio Partners, Bpifrance Large Venture, Merck's M Ventures, and Johnson & Johnson Development Corporation (JJDC), plus €10.4M from the French government via France 2030, shifting focus to Lakhesys™ development and market launch.[2][6]
Astraveus stands out in CGT manufacturing through these key strengths:
Astraveus rides the cell and gene therapy boom, where CAR-T successes like Kymriah highlight efficacy but manufacturing bottlenecks—high costs ($300K+ per dose), centralized facilities, and scalability limits—hinder broader adoption.[1][3] Timing aligns with post-2020 CGT market growth (projected $50B+ by 2030) and regulatory pushes for decentralized production, amplified by France 2030 investments in biotech sovereignty.[2] Market forces like rising therapy demand, lentiviral vector shortages, and AI/microfluidics convergence favor Astraveus, positioning it to democratize access, lower barriers for smaller biotechs, and influence ecosystem shifts toward automated, efficient CGT standards.[1][3][4]
Astraveus is primed for Lakhesys™ commercialization in 2026+, with NecstGen pilots validating real-world use and hiring signaling scale-up.[1][2] Trends like decentralized manufacturing, AI-optimized bioprocessing, and expanding CGT pipelines (e.g., solid tumors, autoimmunity) will propel growth, potentially capturing share in a market starved for cost-effective solutions.[3][4] Its influence may evolve from innovator to ecosystem enabler, partnering with big pharma for next-gen therapies and setting microfluidics as CGT gold standard—echoing its founding vision of biotech's industrial revolution, making advanced treatments accessible to save more lives.[2][3][4]
Astraveus has raised $18.0M in total across 1 funding round.
Astraveus's investors include Advent Life Sciences, Johnson & Johnson Innovation, Pureos Bioventures.
Astraveus has raised $18.0M across 1 funding round. Most recently, it raised $18.0M Seed in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $18.0M Seed | Advent Life Sciences, Johnson & Johnson Innovation, Pureos Bioventures |